



**Division of Health Care, Quality, Financing and Purchasing  
Center for Operations and Pharmacy Management  
Pharmacy and Therapeutics Committee Meeting Minutes  
Tuesday September 18, 2007  
8:00 AM  
EDS  
171 Service Avenue Building 1 Suite 100  
Warwick, Rhode Island**

P&T Members Present: Rita Marcoux, RPh, MBA, Co-chairperson  
David Feeney, RPh, Chairperson  
Gregory Allen, MD  
Richard Wagner, MD  
Charles Gross

Others Present: Paula Avarista, RPh, MBA (RI Medical Assistance Program)  
Ray Maxim, MD (RI Medical Assistance)  
Janice McMahon, RN (Electronic Data Systems)  
Ann Bennett (Electronic Data Systems)  
Karen Mariano, RPh (Electronic Data Systems)  
Chris Andrews, Pharm D (Coventry Health Systems)

The meeting was called to order by Chairperson Feeney at 8:05 AM. The committee reviewed the meeting minutes from the previous meeting. Approval of the minutes were tabled because of missing information concerning drug classes put on hold at the last meeting. They will be reviewed again at the next meeting. It was decided that the NSAIDS and the narcotics would be put on the PDL with preferred status. Dr. Wagner requested that any information (ie. letter) sent directly to a committee member on a drug class under review should document any affiliation with a pharmaceutical manufacturer. It was also decided that the committee would expand to include two more physicians.

The public comment portion of the meeting began next. Representatives from the following pharmaceutical manufacturing companies gave presentations: Alcon, Boehringer Ingelheim, Ortho Biotec, Roche, Schering Plough, Shire, GalxoSmith Kline and Pfizer.

Chris Andrews from Coventry Health Systems gave an overview of the drug classes that were on the agenda to be reviewed. A discussion among the committee members followed each class review. Voting took place after each review. It was decided to table the growth hormones until the next meeting to review the current prior authorizations decisions. More than half of the people on this current therapy were on a medication that was being recommended for non-preferred status and the committee felt further information was needed. It was also decided that the current people taking Lumigan would be granted a three-month extension so their physicians can evaluate the change over to a preferred medication.

The chairperson adjourned the meeting at 10:25 AM.